According to Lukang Pharmaceutical's announcement, the company recently received the “Drug Registration Certificate” for vonoracin fumarate tablets and the “Notice of Approval of the Marketing Application for Chemical Ingredient” for the raw ingredient vonolac fumarate issued by the State Drug Administration. This drug is suitable for reflux esophagitis and the elimination of Helicobacter pylori. Domestic sales in 2025 are about 1,210 million yuan, and the company's total R&D investment is about 13.34 million yuan. This approval will enrich the company's product line and enhance market competitiveness.

According to Lukang Pharmaceutical's announcement, the company recently received the “Drug Registration Certificate” for vonoracin fumarate tablets and the “Notice of Approval of the Marketing Application for Chemical Ingredient” for the raw ingredient vonolac fumarate issued by the State Drug Administration. This drug is suitable for reflux esophagitis and the elimination of Helicobacter pylori. Domestic sales in 2025 are about 1,210 million yuan, and the company's total R&D investment is about 13.34 million yuan. This approval will enrich the company's product line and enhance market competitiveness.